非小细胞肺癌新辅助治疗疗效病理评估专家共识

2021-09-08 国家肿瘤质控中心肺癌质控专家委员会 中华病理学杂志, 2021,50(09)

随着非小细胞肺癌新辅助治疗的进展,与疗效和预后密切相关的病理反应评估得到广泛应用,但需要进一步规范化。本共识在参考国际肺癌研究协会出版的共识基础上,结合专家组临床实践数据及经验,并经反复讨论,由病理医

中文标题:

非小细胞肺癌新辅助治疗疗效病理评估专家共识

发布日期:

2021-09-08

简要介绍:

随着非小细胞肺癌新辅助治疗的进展,与疗效和预后密切相关的病理反应评估得到广泛应用,但需要进一步规范化。本共识在参考国际肺癌研究协会出版的共识基础上,结合专家组临床实践数据及经验,并经反复讨论,由病理医师与临床医师共同制定,涵盖了临床所需提供的关于新辅助治疗标本的临床信息、标本的规范化取材、病理反应评估、病理分期及病理诊断报告等内容,旨在进一步提高新辅助治疗病理学评估的准确性和一致性,为临床进一步治疗和预后预测提供可靠依据。

相关资料下载:
[AttachmentFileName(sort=1, fileName=非小细胞肺癌新辅助治疗疗效病理评估专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=043611c0021950e6, title=非小细胞肺癌新辅助治疗疗效病理评估专家共识, enTitle=, guiderFrom=中华病理学杂志, 2021,50(09), authorId=0, author=, summary=随着非小细胞肺癌新辅助治疗的进展,与疗效和预后密切相关的病理反应评估得到广泛应用,但需要进一步规范化。本共识在参考国际肺癌研究协会出版的共识基础上,结合专家组临床实践数据及经验,并经反复讨论,由病理医, cover=https://img.medsci.cn/2021928/1632844628977_2020535.jpg, journalId=0, articlesId=null, associationId=1990, associationName=国家肿瘤质控中心肺癌质控专家委员会, associationIntro=国家肿瘤质控中心肺癌质控专家委员会, copyright=0, guiderPublishedTime=Wed Sep 08 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="article_abstract" style="color: #2c3e50;" data-v-da075436=""><span data-v-da075436="">随着非小细胞肺癌新辅助治疗的进展,与疗效和预后密切相关的病理反应评估得到广泛应用,但需要进一步规范化。本共识在参考国际肺癌研究协会出版的共识基础上,结合专家组临床实践数据及经验,并经反复讨论,由病理医师与临床医师共同制定,涵盖了临床所需提供的关于新辅助治疗标本的临床信息、标本的规范化取材、病理反应评估、病理分期及病理诊断报告等内容,旨在进一步提高新辅助治疗病理学评估的准确性和一致性,为临床进一步治疗和预后预测提供可靠依据。</span></div>, tagList=[TagDto(tagId=276, tagName=非小细胞肺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=276, guiderKeyword=非小细胞肺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4046, appHits=211, showAppHits=0, pcHits=1493, showPcHits=3831, likes=2, shares=11, comments=12, approvalStatus=1, publishedTime=Wed Sep 29 00:47:26 CST 2021, publishedTimeString=2021-09-08, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=qiushida2, createdTime=Tue Sep 28 23:57:19 CST 2021, updatedBy=6459136, updatedName=艺玮, updatedTime=Thu Jan 04 23:27:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=非小细胞肺癌新辅助治疗疗效病理评估专家共识.pdf)])
非小细胞肺癌新辅助治疗疗效病理评估专家共识.pdf
下载请点击:
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2174328, encodeId=7e5821e432853, content=如何下载 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43249104422, createdName=ms3000000197638389, createdTime=Mon Dec 11 21:14:19 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1184442, encodeId=16df1184442a8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2e02031311, createdName=9700, createdTime=Sat Jan 15 00:23:55 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182295, encodeId=7bc711822952e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44d96158448, createdName=ms4000000949064447, createdTime=Sat Jan 08 17:40:08 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181924, encodeId=0e22118192465, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200830/c5d4eaa7f91746ae91939d37dac1b9ac/20e45e8069924d3295d5cfa3c464fa92.jpg, createdBy=06ce5329129, createdName=zZ大壮哥, createdTime=Fri Jan 07 18:21:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084552, encodeId=d6e21084552dd, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d11f5401919, createdName=ms9000001978514961, createdTime=Mon Dec 27 01:59:12 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2023-12-11 ms3000000197638389 来自江苏省

    如何下载

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2174328, encodeId=7e5821e432853, content=如何下载 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43249104422, createdName=ms3000000197638389, createdTime=Mon Dec 11 21:14:19 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1184442, encodeId=16df1184442a8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2e02031311, createdName=9700, createdTime=Sat Jan 15 00:23:55 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182295, encodeId=7bc711822952e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44d96158448, createdName=ms4000000949064447, createdTime=Sat Jan 08 17:40:08 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181924, encodeId=0e22118192465, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200830/c5d4eaa7f91746ae91939d37dac1b9ac/20e45e8069924d3295d5cfa3c464fa92.jpg, createdBy=06ce5329129, createdName=zZ大壮哥, createdTime=Fri Jan 07 18:21:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084552, encodeId=d6e21084552dd, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d11f5401919, createdName=ms9000001978514961, createdTime=Mon Dec 27 01:59:12 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2022-01-15 9700

    谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2174328, encodeId=7e5821e432853, content=如何下载 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43249104422, createdName=ms3000000197638389, createdTime=Mon Dec 11 21:14:19 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1184442, encodeId=16df1184442a8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2e02031311, createdName=9700, createdTime=Sat Jan 15 00:23:55 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182295, encodeId=7bc711822952e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44d96158448, createdName=ms4000000949064447, createdTime=Sat Jan 08 17:40:08 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181924, encodeId=0e22118192465, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200830/c5d4eaa7f91746ae91939d37dac1b9ac/20e45e8069924d3295d5cfa3c464fa92.jpg, createdBy=06ce5329129, createdName=zZ大壮哥, createdTime=Fri Jan 07 18:21:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084552, encodeId=d6e21084552dd, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d11f5401919, createdName=ms9000001978514961, createdTime=Mon Dec 27 01:59:12 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2022-01-08 ms4000000949064447

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2174328, encodeId=7e5821e432853, content=如何下载 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43249104422, createdName=ms3000000197638389, createdTime=Mon Dec 11 21:14:19 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1184442, encodeId=16df1184442a8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2e02031311, createdName=9700, createdTime=Sat Jan 15 00:23:55 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182295, encodeId=7bc711822952e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44d96158448, createdName=ms4000000949064447, createdTime=Sat Jan 08 17:40:08 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181924, encodeId=0e22118192465, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200830/c5d4eaa7f91746ae91939d37dac1b9ac/20e45e8069924d3295d5cfa3c464fa92.jpg, createdBy=06ce5329129, createdName=zZ大壮哥, createdTime=Fri Jan 07 18:21:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084552, encodeId=d6e21084552dd, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d11f5401919, createdName=ms9000001978514961, createdTime=Mon Dec 27 01:59:12 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2022-01-07 zZ大壮哥

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2174328, encodeId=7e5821e432853, content=如何下载 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43249104422, createdName=ms3000000197638389, createdTime=Mon Dec 11 21:14:19 CST 2023, time=2023-12-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1184442, encodeId=16df1184442a8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2e02031311, createdName=9700, createdTime=Sat Jan 15 00:23:55 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182295, encodeId=7bc711822952e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44d96158448, createdName=ms4000000949064447, createdTime=Sat Jan 08 17:40:08 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181924, encodeId=0e22118192465, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200830/c5d4eaa7f91746ae91939d37dac1b9ac/20e45e8069924d3295d5cfa3c464fa92.jpg, createdBy=06ce5329129, createdName=zZ大壮哥, createdTime=Fri Jan 07 18:21:19 CST 2022, time=2022-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084552, encodeId=d6e21084552dd, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d11f5401919, createdName=ms9000001978514961, createdTime=Mon Dec 27 01:59:12 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2021-12-27 ms9000001978514961

    值得学习

    0

拓展阅读

ASCO指南:IV期非小细胞肺癌的维持治疗(2009)

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2009-12-20

2010CCO 晚期非小细胞肺癌一线全身化疗

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2010-01-01

2010ESMO临床实践指南:早期和局部晚期(非转移性)非小细胞肺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01

2010ESMO临床实践指南:转移性非小细胞肺癌的诊断、治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01